IDPNHD: Intradialytic Parenteral Nutrition in Hemodialysis Patients

Sponsor
Fresenius Kabi (Industry)
Overall Status
Completed
CT.gov ID
NCT00501956
Collaborator
Institute for Clinical Research (Other)
140
1
2
77
1.8

Study Details

Study Description

Brief Summary

Malnutrition is a major cause of death in chronic hemodialysis patients. Primary treatment of malnutrition in these patients is dietetic counseling, additional enteral nutrition and occasionally drug therapy.

In cases where primary treatment of malnutrition is not effective, intradialytic parenteral nutrition (IDPN)during dialysis therapy may be administered. Using IDPN aminoacids, carbohydrates and fatty acids as well as vitamins and trace elements can be given to the patients.

Effectiveness of IDPN has to be verified.

Condition or Disease Intervention/Treatment Phase
  • Drug: Intradialytic Parenteral Nutrition (IDPN)
Phase 4

Detailed Description

25% of hemodialysis patients who are treated for more than 5 years suffer from protein malnutrition. 7% have a protein catabolic rate less than 0,6 g/kgBW and day.

The conventional treatment of malnutrition include dietetic counseling, psychologic advice and giving additional oral nutrients.In many cases this kind of therapy is uneffective. If supplementary enteral nutrition is used, the additional intake of water has to be taken into consideration.

IDPN is a mode of treatment by which disadvantages of enteral nutrition and fluid overload of the patients can be avoided.During each dialysis session nutrients can be given and additional water simultaneously can be removed by ultrafiltration.

Some publications have shown that the catabolic state of the patients can be converted into an anabolic state. There are only small randomized studies showing the positive effect of IDPN.

In this german multicenter study malnourished hemodialysis patients are randomized into two groups. One group is treated with IDPN during each dialysis session for 16 weeks followed by 12 weeks of follow-up without IDPN. The control-group does not receive IDPN.

The parameters of metabolism are: Albumin, prealbumin, transferrin, phase angle alpha (bioimpedance), proteincatabolic rate (formal urea kinetics), BMI and subjective global assessment (SGA score).

Study Design

Study Type:
Interventional
Actual Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Study on the Effect of Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients
Study Start Date :
Jul 1, 2004
Actual Primary Completion Date :
Dec 1, 2010
Actual Study Completion Date :
Dec 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intradialytic parenteral nutrition

Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.

Drug: Intradialytic Parenteral Nutrition (IDPN)
compounded IDPN, 3 x/week, 16 weeks intervention
Other Names:
  • Individually compounded parenteral nutrition
  • No Intervention: Control Group

    Observation over 28 weeks (16 + 12 weeks).

    Outcome Measures

    Primary Outcome Measures

    1. Change in prealbumin levels [8 weeks]

    Secondary Outcome Measures

    1. Serum albumin, transferrin, nutritional status [8 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • hemodialysis therapy more than 6 months

    • three times per week hemodialysis

    • albumin < 35 g/l

    • prealbumin < 250 mg/l

    • phase angle < 4,5°

    • SGA score grade B or C

    • informed consent

    Exclusion Criteria:
    • inadequate dialysis (Kt/V < 1,2)

    • chemotherapy or radiotherapy

    • cardiac pacemaker

    • acute bacterial infection

    • acute immunological disease

    • cancer disease

    • severe hepatic insufficiency

    • interferon therapy

    • HIV disease

    • severe diabetes mellitus

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Interneph e.V. Institute for Applied Nephrology Aachen Germany 52074

    Sponsors and Collaborators

    • Fresenius Kabi
    • Institute for Clinical Research

    Investigators

    • Principal Investigator: Helmut Mann, Prof. Dr., Interneph e.V, Aachen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Fresenius Kabi
    ClinicalTrials.gov Identifier:
    NCT00501956
    Other Study ID Numbers:
    • IDPN 24332
    First Posted:
    Jul 17, 2007
    Last Update Posted:
    Mar 3, 2016
    Last Verified:
    Mar 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Fresenius Kabi
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 3, 2016